Video

Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLC

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Sreeni Chittoor, MD, FACP, a medical oncologist and hematologist at Texas Oncology, discusses targetable mutations and respective treatment options for patients with metastatic non—small cell lung cancer (NSCLC).

When performing molecular tests on patients with metastatic NSCLC, the focus is typically on EGFR, ROS1, ALK, BRAF, NTRK, RET, MET, AKT1, PTEN, and HER2 mutations, as these are druggable targets, explains Chittoor.

Some mutations have more than 1 treatment available. For example, if a patient has an exon 19 deletion, patients can receive or gefitinib (Iressa), erlotinib (Tarceva), or osimertinib (Tagrisso) in the first-line setting. Osimertinib, a third-generation EGFR TKI, was compared head-to-head with first-generation gefitinib and second-generation erlotinib. Results showed a significant improvement in progression-free survival and duration of response. Osimertinib also crosses the blood-brain barrier. With 3 EGFR TKIs approved for use in NSCLC, data must be considered carefully when choosing a treatment for a patient with an EGFR-activating mutation, concludes Chittoor.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity